FDA Adds RA Indication for Riabni Rituximab Biosimilar

Riabni is the second rituximab biosimilar to be approved for rheumatoid arthritis in the United States.

Related Keywords

United States , ,Amgen ,European Union ,Drug Administration ,Disease Activity Score ,Rheumatoid Arthritis ,A ,Chronic Lymphocytic Leukemia ,Hematology ,Microscopic Polyangiitis ,Non Hodgkins Lymphoma ,Vasculitis ,Wegeners Granulomatosis ,Wegener Granulomatosis ,Antineoplastic Drug ,Nti Cancer Agents ,Evacizumab ,Rlotinib ,Efitinib ,Matinib ,Ituximab ,U11248 ,Unitinib ,Rastuzumab ,Biologic Therapy ,Monoclonal Antibody ,Etuximab ,Biosimilars ,Biosimilar Drugs ,Ollow O ,